Labetalol tablet shortage prompts substitution changes and overseas supply
28 Jan 2026
While an earlier shortage of Presolol 100 mg tablets was resolved in December 2025, supply constraints now affect the 200 mg strength. To maintain patient access, an overseas-registered labetalol hydrochloride 200 mg tablet has been approved for supply under section 19A of the Therapeutic Goods Act 1989.
In response to the shortage, a new Serious Scarcity Substitution Instrument (SSSI) has also been introduced. This allows pharmacists, where appropriate, to supply an equivalent quantity using a different tablet strength without requiring a new prescription.
Under the SSSI:
-
If Presolol 200 mg is prescribed but unavailable, Presolol 100 mg tablets may be supplied in an equivalent dose.
-
If Presolol 100 mg is prescribed but unavailable, Presolol 200 mg tablets may be supplied.
Further information for pharmacists, prescribers and patients — including details on the shortage, substitution arrangements and the overseas-registered alternative — is available on the Presolol shortage information page.
Source: Therapeutic Goods Administration (TGA)
